Skip to main content

Closed

DNLI: Denali Therapeutics Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Operating margin0.0%

ROIC-46.9%

Financially safe

Stretched

Debt / equity0.04×

Interest coverage0.0×

Current ratio9.28×

Denali Therapeutics Inc.

DNLINASDAQ Global Select·USD·Closed

Denali Therapeutics Inc.

DNLINASDAQ·USD·Closed

$23.02

−5.46%

$23.02

−$1.33 (5.46%)

52W Range

71thpctl

Volume

0.64×avg

Mkt Cap

3.65BUSD

P/E

-8.0TTM

Div Yield

–ann

52W Range

71thpctl

Volume

0.64×avg

Market Cap

3.65BUSD

P/E Ratio

-8.0TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings